Logo
x

Search

Subscribe Now

RA

Celltrion Presents Results of CT-P17 (biosimilar- adalimumab) in P-III Study for RA at ACR 2020

Celltrion Presents Results of CT-P17 (biosimilar- adalimumab) in P-III Study for RA at ACR 2020

  • November 3, 2020
Gilead and Galapagos' Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

Gilead and Galapagos' Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

  • March 29, 2019
Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) in Japan

Lupin and YL Biologics' Etanercept Biosimilar (YLB113) Receive PMDA's Approval for Moderate-to-Severe Rheumatoid Arthritis (RA) an...

  • March 26, 2019
Amgen and Allergan Report Results of ABP 798 (rituximab- biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Arthritis (RA)

Amgen and Allergan Report Results of ABP 798 (rituximab- biosimilar) in P-I/III (NCT02792699) for Moderate-To-Severe Rheumatoid Ar...

  • January 24, 2019
Genentech's ACTpen Receives FDA's Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA)- Giant Cell Arteritis (GCA) and Two Forms of Juvenile Arthritis

Genentech's ACTpen Receives FDA's Approval for Actemra (tocilizumab) to Treat Rheumatoid Arthritis (RA)- Giant Cell Arteritis (GCA...

  • November 27, 2018
Eli Lilly's Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults

Eli Lilly's Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults

  • October 8, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.